Filing Flows › Coya Therapeutics (COYA) › Q3 2025
Coya Therapeutics (COYA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Coya Therapeutics (COYA) reported revenue of $3.6M for the third quarter 2025 (Q3 2025) and up 22-fold from the quarter before. Operating margin was -68.3%, net loss $2.1M (59.4% of revenue).
Coya Therapeutics, Q3 2025: revenue $3.6M, operating margin -68.3%, net loss $2.1M, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.6M | 22× | — |
| Operating profit | −$2.4M | — | — |
| Net earnings | −$2.1M | — | — |
| Operating cash flow | −$1.1M | — | — |
What changed
Revenue was $3.6M in Q3 2025, up 2078% from the previous quarter.
Operating costs exceeded revenue by $2.4M, an operating margin of -68.3%. The quarter ended with a net loss of $2.1M, narrower than the previous quarter's $6.1M loss.
Operating cash flow was −$1.1M. Non-cash charges added back $7K of depreciation and $1.1M of share-based compensation. Working capital and other items used $93K.
Questions
What was Coya Therapeutics' revenue in the third quarter 2025?
Coya Therapeutics (COYA) reported revenue of $3.6M for the third quarter 2025 (Q3 2025) and up 22-fold from the quarter before.
Was Coya Therapeutics profitable in the third quarter 2025?
Operating loss was $2.4M (-68.3% of revenue) and net loss $2.1M.
Source: Coya Therapeutics 10-Q on SEC EDGAR.